AGP Executive Report
Last update: 3 hours agoDrug Access: Aspen Pharmacare won approval for generic injectable semaglutide in Brazil and South Africa, with launches expected in the coming months—potentially widening access to diabetes and weight-loss treatment. Medicine Safety: The FDA warned of a rare eye condition linked to some GLP-1 drugs. Separately, a doctor cautioned that chatbot advice can be dangerous after a woman with epilepsy reportedly reduced her medication on ChatGPT’s advice and died. Care Access: France plans to add 70 mobile clinics, aiming for more than 100 by 2027 to serve communities short of doctors. New Treatment: Early CAR-T results in stiff-person syndrome were striking: two trial participants regained everyday abilities, though the findings are preliminary. Drug Quality: Nigeria’s NAFDAC urged medicine sellers to watch for fake and unregistered drugs and buy only from authorised suppliers.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
